AQR Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-13,334
Closed -$502K 2341
2021
Q1
$502K Sell
13,334
-47,558
-78% -$1.19M ﹤0.01% 1836
2020
Q4
$1.04M Sell
60,892
-160,485
-72% -$2.01M ﹤0.01% 1495
2020
Q3
$1.04M Sell
221,377
-129,553
-37% -$658K ﹤0.01% 1394
2020
Q2
$2.14M Sell
350,930
-56,312
-14% -$232K ﹤0.01% 1129
2020
Q1
$924K Sell
407,242
-42,161
-9% -$179K ﹤0.01% 1369
2019
Q4
$2.06M Buy
449,403
+311,832
+227% +$1.24M ﹤0.01% 1261
2019
Q3
$533K Buy
+137,571
New +$755K ﹤0.01% 1741
2018
Q1
Sell
-20,255
Closed -$444K 2297
2017
Q4
$444K Buy
20,255
+10,287
+103% +$331K ﹤0.01% 1955
2017
Q3
$408K Buy
9,968
+3,166
+47% +$99.4K ﹤0.01% 2003
2017
Q2
$205K Sell
6,802
-53,150
-89% -$1.66M ﹤0.01% 2123
2017
Q1
$2.17M Sell
59,952
-68,143
-53% -$3M ﹤0.01% 1346
2016
Q4
$6.42M Sell
128,095
-54,813
-30% -$2.88M 0.01% 927
2016
Q3
$9.6M Buy
182,908
+62,786
+52% +$3M 0.01% 780
2016
Q2
$4.97M Buy
120,122
+68,943
+135% +$3M 0.01% 918
2016
Q1
$2.08M Sell
51,179
-35,304
-41% -$1.21M ﹤0.01% 1227
2015
Q4
$3.59M Sell
86,483
-43,965
-34% -$1.47M 0.01% 1017
2015
Q3
$2.01M Sell
130,448
-36,930
-22% -$794K ﹤0.01% 1130
2015
Q2
$4.16M Buy
167,378
+76,178
+84% +$1.7M 0.01% 899
2015
Q1
$2.08M Buy
+91,200
New +$2.3M ﹤0.01% 1089

AQR Capital Management's FPRX Position: Q2 2021 in Review

AQR Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 13,334 shares — an estimated $502K sold.

AQR Capital Management first reported a position in FPRX in Q1 2015 and held it in 19 quarters. The position peaked at $9.6M in Q3 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

  • AQR Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • AQR Capital Management sold 13,334 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $502K.
  • AQR Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 19 quarters.
  • AQR Capital Management's Five Prime Therapeutics, Inc. position peaked at $9.6M in Q3 2016.
  • 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on AQR Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.